This first-of-its-kind infant care collaboration for Owlet enables clinicians to access Owlet’s data through Locus Health’s platform, enhancing visibility, improving care continuity, and supporting families after hospital discharge.
LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor—Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces a partnership with Locus Health, a leader in remote patient monitoring, for more integrated infant health management. The collaboration connects data from Owlet’s FDA-cleared prescription device, BabySat®, directly into the Locus Health platform, giving healthcare providers ongoing and secure access to vital infant health information after hospital discharge.
“For families and healthcare systems alike, the transition from hospital to home represents both a challenge and a tremendous opportunity to improve outcomes,” said Jonathan Harris, Owlet’s President and CEO. “By integrating Owlet’s technology with Locus Health, we’re extending our mission beyond the nursery by connecting our proven monitoring capabilities directly into clinical workflows. Together, we’re helping hospitals scale connected care and supporting families with the confidence and continuity they deserve.”
The Critical Role of Clinician Oversight in Home Monitoring
Each year, nearly 500,000 babies transition home from an ICU across the U.S., many with ongoing medical needs that require continued monitoring. This collaboration helps clinicians bridge that crucial gap between hospital and home, enabling more connected care for vulnerable infants. The integration supports monitoring of infants with complex conditions such as congenital heart defects, chronic lung disease, and arrhythmia management.
“Locus Health has long been a leader in remote care management software for vulnerable pediatric patients, their families, and hospital care teams,” said Andy Archer, Locus Health’s co-founder and CEO. “Our outcomes-based solutions for populations like congenital heart disease and neonatal ICU patients will be further enhanced with a partner like Owlet, providing vital biometric data through the Locus platform to care teams that increasingly need both timely insights and enhanced workflow efficiency.”
Providers using Locus Health will have access to patient data collected by BabySat, allowing them to remotely track key vital signs like oxygen saturation and pulse rate, help detect concerning trends early, and support timely intervention, all within the same clinical tools and workflows they already rely on. By delivering frequent, automated data updates, the integration eliminates manual data entry and minimizes the risk of transcription errors. The goal is more accurate insights, better-informed clinical decisions, and improved outcomes, without adding workflow complexity for clinicians or burden on parents during what can be a very difficult time.
Empowering Families and Advancing Connected Care
This partnership reflects Owlet’s commitment to accessible, high-quality care for infants and their families, and marks an important step in expanding its clinical and enterprise partnerships in the pediatric healthcare space.
“Owlet has monitored more than 2.5 million babies, equipping parents and caregivers with clinically proven, reliable tools to track Baby’s key vitals,” said Dean Demitropoulos, Senior Director of Business Development at Owlet. “Our growing footprint in the medical space, and collaboration with a pediatric market leader like Locus, underscores our vision to make health insights accessible at home for infants that require monitoring, bringing families and care teams together through connectivity.”
For more information on Owlet’s products, including both FDA-cleared BabySat and Dream Sock®, visit www.owletcare.com. For more information on Locus Health’s product and platform solutions, visit www.locushealth.com.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children’s well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About Locus Health
Locus is making the promise of remote patient monitoring and electronic medical record integration a reality for a wide range of populations, supporting care teams’ ability to monitor patients and provide coordinated support. The Locus platform is used at many health systems across the US and in Canada, including multiple top Children’s Hospitals, and has been developed in part through a Small Business Innovation (SBIR) Award by the National Cancer Institute (NCI). For more information on our remote care management solution and to request a demo, visit www.locushealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the outcomes and benefits of Owlet’s partnership with Locus Health and the integration of infant health insights from BabySat® into Locus Health’s remote patient monitoring (RPM) platform and related clinical workflows, including potential improvements in patient care coordination, workflow efficiency, and post-discharge monitoring; the scope, timing, commercial adoption and performance of the integration; the ability of healthcare providers to scale remote patient monitoring programs and access real-time insights; the Company’s product roadmap and growth prospects; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the Locus Health-enabled integration; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with Locus Health and other third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
Contacts
Owlet Media Contact:
[email protected]
Owlet Investor Contact:
[email protected]
Owlet Health Contact:
[email protected]
Locus Health Contact:
[email protected]
